We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our
Privacy Policy
Profacgen's Microbiological & Safety Testing service provides comprehensive, regulatory-compliant detection and quantification of microbial contaminants, endotoxins, mycoplasmas, and adventitious agents across your biopharmaceutical development and manufacturing workflow. From cell bank characterization and raw material qualification to drug substance release and environmental monitoring, we ensure microbial safety at every critical control point.
Microbiological contamination is not merely a quality deviation—it is a patient safety imperative. A single undetected mycoplasma event, endotoxin excursion, or sterility failure can halt clinical trials, trigger regulatory action, and compromise years of development investment. The ability to detect, quantify, and eliminate these risks with validated, phase-appropriate methods underpins every successful biopharmaceutical program.
What Challenges Do We Solve?
Figure 1. Critical control points for microbiological and safety testing across upstream and downstream operations.
Biopharmaceutical development teams face escalating regulatory expectations and operational complexity in ensuring microbial safety. Key analytical and strategic challenges include:
Detecting bacterial endotoxins with sensitivity appropriate to parenteral dosing regimens, while navigating the transition from Limulus amebocyte lysate (LAL) to recombinant Factor C (rFC) methods under USP <1085.1> and Ph. Eur. 2.6.32
Demonstrating sterility assurance and bioburden control for aseptically processed biologics, cell therapies, and gene therapy vectors where terminal sterilization is not feasible
Detecting mycoplasma contamination with rapid molecular methods that reduce hold times from 28 days to 24–72 hours without sacrificing compendial compliance
Validating viral clearance and adventitious agent screening for cell substrates, viral seeds, and unprocessed bulk to satisfy ICH Q5A(R2) and regional biosafety expectations
Investigating low endotoxin recovery (LER), bacteriostasis, or fungistasis interference that compromises method reliability and batch release timelines
Designing environmental monitoring (EM) programs and contamination control strategies that align with facility classification, process risk, and regulatory inspection readiness
Compiling CMC and quality control documentation that satisfies FDA, EMA, PMDA, and NMPA expectations for IND, BLA, and commercial release
Addressing these challenges requires more than compendial box-checking. It demands an integrated microbiological testing architecture that connects detection science to process control, risk assessment, and regulatory strategy.
Profacgen's value drivers include:
Platform-agnostic method selection spanning traditional compendial, rapid microbial, and molecular diagnostic technologies
Phase-appropriate validation from preclinical screening to GMP batch release with pre-established acceptance criteria and system suitability
Direct integration with process development, manufacturing, and quality teams for real-time contamination investigation and corrective action
Regulatory-ready documentation designed for seamless IND, BLA, and post-approval submission without agency query cycles
These priorities ensure your program advances with confidence, knowing that microbial safety is assured by validated data rather than procedural assumption.
When to Consider Microbiological & Safety Testing
Microbiological & Safety Testing is most relevant when:
Master and working cell banks (MCB/WCB) require comprehensive characterization for adventitious agents, mycoplasma, and sterility prior to IND submission
Raw materials, media, buffers, and excipients require qualification to prevent upstream introduction of bioburden or endotoxin into the manufacturing stream
In-process and drug substance batches require release testing under GMP to demonstrate compliance with sterility, endotoxin, and bioburden specifications
Environmental monitoring data trends indicate potential loss of environmental control, requiring investigative support and remediation validation
Process changes—such as single-use system adoption, filter changes, or facility modifications—require re-validation of microbial clearance and safety assurance
Regulatory observations, complete response letters, or pre-approval inspection findings demand enhanced microbial testing, method remediation, or additional validation data
This service is particularly effective for teams that seek to embed microbial safety into process design and facility operations rather than treating it as an isolated QC checkpoint.
Our Core Platforms
Profacgen provides a structured, quality-oriented Microbiological & Safety Testing service that aligns analytical methodology with your specific product class, manufacturing process, and regulatory jurisdiction.
Our Bacterial Endotoxin Testing platform encompasses gel-clot, dynamic chromogenic, and dynamic turbidimetric LAL methods compliant with USP <85> and EP 2.6.14. We also offer recombinant Factor C (rFC) assays aligned with Ph. Eur. 2.6.32 and USP <1085.1> for sustainable, horseshoe-crab-independent endotoxin detection. Method development includes interference factor determination, LER investigation, and product-specific validation to ensure reliable quantification across formulation matrices.
The Sterility and Bioburden Testing service delivers compendial membrane filtration and direct inoculation sterility testing per USP <71> and EP 2.6.1, alongside microbial enumeration (USP <61>) and specified organism detection (USP <62>). We support rapid microbial methods (RMM) including ATP bioluminescence and solid-phase cytometry for in-process monitoring, and provide bacteriostasis/fungistasis validation to eliminate false-negative risk in sterility assurance.
Our Mycoplasma Detection platform integrates compendial culture methods (USP <63>, EP 2.6.7) with validated qPCR, digital PCR, and indicator cell (DNA staining) assays for comprehensive coverage. Rapid nucleic acid testing reduces detection turnaround from 28 days to 24–72 hours while maintaining regulatory acceptability. We support cell bank characterization, raw material screening, and facility contamination investigations with full documentation for regulatory filing.
Regulatory-Centric Method Design: Every assay is architected with end-game filing requirements in mind, ensuring data packages withstand FDA, EMA, PMDA, and NMPA scrutiny from IND through commercial license application.
Multi-Platform Microbiological Coverage: No single technique addresses every microbial risk. Our integration of compendial, rapid microbial, and molecular diagnostic platforms eliminates detection blind spots and supports comprehensive contamination control strategies.
Phase-Appropriate Agility: From preclinical screening assays to fully validated GMP release methods, we scale testing rigor, system suitability criteria, and documentation to match your precise program milestone and budget.
Integrated CMC & QC Support: Microbiological data feeds directly into our process development, manufacturing, and quality teams, enabling rapid root-cause investigation, corrective action, and streamlined tech transfer to your commercial partner.
Application Scenarios
Scenario 1: Endotoxin Method Remediation for a Parenteral Biosimilar
Program Context:
A biosimilar developer encountered recurrent low endotoxin recovery (LER) in a high-concentration monoclonal antibody formulation, causing failed release testing, batch delays, and escalating FDA scrutiny during a pre-approval inspection.
Objective:
Identify the physicochemical root cause of LER, develop a validated recovery strategy, and restore reliable endotoxin quantification to prevent further batch release failures.
Approach:
Profacgen conducted a systematic LER investigation per USP <1085.1>, evaluating pH, protein concentration, polysorbate content, and chelator effects on endotoxin spike recovery. A modified sample preparation protocol with pH adjustment and surfactant optimization was developed, followed by full validation against USP <85> accuracy, precision, and specificity criteria.
Outcome:
Endotoxin recovery improved from 18% to 98%, batch release resumed without formulation changes, and the validation package closed the regulatory agency's inspection observation with zero follow-up queries. This preserved the BLA timeline.
Scenario 2: Rapid Mycoplasma Response for an Allogeneic Cell Therapy
Program Context:
An allogeneic cell therapy manufacturer detected a mycoplasma-positive signal in a working cell bank (WCB) via an in-house PCR screen, threatening the entire clinical supply chain and requiring immediate contamination source identification and facility remediation.
Objective:
Confirm the mycoplasma finding with compendial culture and indicator cell methods, identify the contaminant species and entry route, and validate a rapid qPCR release assay to prevent future 28-day hold times that jeopardize perishable cell therapy logistics.
Approach:
Profacgen executed EP 2.6.7 culture and DNA staining confirmation, followed by 16S rRNA sequencing for species identification. Environmental monitoring data was statistically reviewed to trace the source to a compromised raw material lot. A validated qPCR method with 24-hour turnaround was developed and qualified against the compendial gold standard.
Outcome:
The facility was successfully remediated, the WCB was replaced with a qualified backup, and the rapid qPCR method was accepted by regulators as a routine release assay—reducing inventory hold time by 27 days and preventing further clinical supply interruption.
Q: What is the difference between LAL and recombinant Factor C (rFC) endotoxin testing?
A: LAL assays rely on amebocyte lysate harvested from horseshoe crabs and detect endotoxin through a protease cascade. rFC is a recombinant protein that specifically binds endotoxin via the Factor C pathway without animal-derived reagents. Both methods are pharmacopoeially recognized, with rFC gaining preference for sustainability and reduced lot-to-lot variability.
Q: What methods are used for mycoplasma detection?
A: We deploy compendial culture methods (USP <63>, EP 2.6.7), indicator cell DNA staining assays, and validated nucleic acid amplification techniques (NAT) including qPCR and digital PCR. NAT methods offer 24–72 hour turnaround compared to 28 days for culture, while maintaining regulatory acceptability when properly validated.
Q: How does rapid microbial testing differ from traditional compendial methods?
A: Rapid microbial methods (RMM) such as ATP bioluminescence, solid-phase cytometry, and flow cytometry detect viable microorganisms in hours rather than days. These methods require validation against the compendial reference to demonstrate equivalent or superior sensitivity, specificity, and robustness prior to regulatory acceptance.
Q: What is low endotoxin recovery (LER) and how is it addressed?
A: LER occurs when formulation components—high protein concentration, chelators, or surfactants—mask endotoxin detection, causing false-negative or under-quantified results. We address LER through systematic hold-time studies, pH and excipient mapping, and modified sample preparation protocols validated per USP <1085.1>.
Q: When is bioburden testing required versus sterility testing?
A: Bioburden testing (microbial enumeration) is required for in-process materials, raw materials, and non-sterile products to monitor microbial load. Sterility testing per USP <71> is mandatory for final drug product release when the product is labeled sterile and intended for parenteral, ophthalmic, or implant administration.
Q: Can you support environmental monitoring program design?
A: Yes. We design, validate, and execute environmental monitoring programs for cleanroom classifications from ISO 5 to ISO 8, including viable and non-viable particle monitoring, surface and personnel sampling, and trend analysis with alert and action limit establishment.
Online Inquiry
Fill out this form and one of our experts will respond to you within one business day.
Figure 1. Critical control points for microbiological and safety testing across upstream and downstream operations.